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Abstract
Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by progressive death
of cerebral and spinal motorneurons. Using behavioral tests we studied the efficiency of gene-
cell therapy in SOD1 G93A transgenic mice receiving xenotransplantation of human umbilical
cord blood mononuclear cells genetically modified with adenoviral vectors encoding vascular
endothelial growth factor (VEGF) and reporter green fluorescent protein (EGFP) genes. The cells
were transplanted to mice on week 27 of life (preclinical stage of the disease). Behavioral tests
(open field, grip strength test) showed that transplantation of umbilical cord blood mononuclear
cells expressing VEGF significantly improved the parameters of motor and explorative activity,
grip  strength,  and  animal  survival.  Thus,  gene-cell  therapy  based  on  genetically  modified
mononuclear cells expressing VEGF can be efficient for the treatment of amyotrophic lateral
sclerosis. © 2013 Springer Science+Business Media New York.
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